Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 1, 2001, Pages 39-46

  Paltiel, A David ^b   Fuhlbrigge, Anne L ^b   Kitch, Barrett T ^b   Liljas, Bengt ^b   Weiss, Scott T ^b   Neumann, Peter J ^b   Kuntz, Karen M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Asthma; Cost effectiveness analysis; Decision analysis; Inhaled corticosteroids; Markov models

Indexed keywords

CORTICOSTEROID;

ARTICLE; ASTHMA; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DYSPHONIA; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION; THRUSH;

EID: 0034923526     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.116289     Document Type: Article

References (79)

1. Forecasted state-specific estimates of self-reported asthma prevalence - United States, 1998
2. Trends in the cost of illness for asthma in the United States, 1985-1994
3. Inhaled glucocorticoids for asthma
4. Inhaled steroids and the risk of hospitalization for asthma
5. Guidelines on the management of asthma
6. Treatment patterns among adult patients with asthma: Factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids
7. Cost-effectiveness in health and medicine
8. Readmission rates are associated with differences in the process of care in acute asthma
9. National Asthma Education and Prevention Program working group report on the cost-effectiveness of asthma care
10. The Markov process in medical prognosis
11. FEV1 is associated with risk of asthma attacks in a pediatric population
12. Relationship between FEV1 and subsequent asthma attacks
13. Physiologic measures: Pulmonary function tests. Asthma outcomes
14. A risk screening questionnaire for adult asthmatics to predict attendance at hospital emergency departments
15. Risk factors for repeat attendance at hospital emergency departments among adults and children with asthma
16. Computer-based models to identify high-risk children with asthma
17. Characteristics of patients with asthma within a large HMO: A comparison by age and gender
18. The influence of age and sex on asthma admissions
19. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma
20. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered dose inhaler in patients with persistent asthma
21. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma
22. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma
23. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma
24. Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma
25. A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma
26. Inhaled steroids and the risk of hospitalization for asthma
27. Comparing asthma care for Medicaid and non-Medicaid children in an HMO
28. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life
29. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects
30. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation
31. Fluticasone propionate compared with theophylline for mild-to-moderate asthma
32. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma
33. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma
34. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma
35. Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma
36. Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmatics
37. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma
38. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma
39. Fluticasone propionate aerosol: Efficacy in patients with mild to moderate asthma
40. A comparison of beclomethasone, salmeterol, and placebo in children with asthma
41. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children
42. National trends in morbidity and mortality of asthma in the US
43. Costs of asthma according to the degree of severity
44. The cost of asthma in the emergency department and hospital
45. A randomized trial of A.C.T. (asthma care training) for kids
46. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: A retrospective, record-based study
47. An economic evaluation of asthma in the United States
48. Emergency room encounters of pediatric patients with asthma: Cost comparisons with other treatment settings
49. Cost of asthma illness: Emergency department visits without admission
50. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease
51. Integrating patient preferences into health outcomes assessment: The multiattribute Asthma Symptom Utility Index
52. Relationship between FEV 1% predicted and utilities in adult asthma
53. Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques
54. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2
55. Efficacy and safety of inhaled corticosteroids. New developments
56. Measuring efficacy and safety of different inhaled corticosteroid preparations
57. Inhaled steroid asthma treatment: "Primum non nocere"
58. Development of a pharmacoeconomic policy model for asthma
59. Cost-effectiveness of coronary artery bypass surgery
60. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
61. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension
62. Cutting into cholesterol: Cost-effective alternatives for treating hypercholesterolemia
63. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
64. The cost-effectiveness of combination antiretroviral therapy in HIV
65. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia
66. Medical management of gallstones: A cost-effectiveness analysis
67. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia
68. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies
69. Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results